https://www.selleckchem.com/mTOR.html https://www.selleckchem.com/mTOR.html Scientific as well as health care development through My own Wellness Record consumption along with education and learning normally exercise (CHIME-GP): a report protocol for any cluster-randomised manipulated demo. New therapeutic options for patients with Crohn's disease (CD) with perianal lesions failing anti-tumor necrosis factor (TNF) agents are needed. We aimed to assess the effectiveness of ustekinumab in perianal CD (pCD) and predictors of clinical success in a real-life multicenter cohort. We conducted a national multicenter retrospective cohort study in patients with either active or inactive pCD who received ustekinumab. In patients with active pCD at treatment initiation, the success of ustekinumab was defined by clinical success at 6 months assessed by the physician's judgment without additional medical or surgical treatment for pCD. Univariate and multivariable logistic regression analyses were performed to identify predictors of success. In patients with inactive pCD at ustekinumab initiation, the pCD recurrence-free survival was calculated using the Kaplan-Meier method. Two hundred seven patients were included, the mean age was 37.7 years, the mean duration of CD was 14.3 years, and the mean number l effective therapeutic option in perianal refractory CD. Further prospective studies are warranted. Most of the kidney dysfunction in HIV positive children receiving antiretroviral therapy (ART) is attributed to tenofovir. There is a paucity of data on kidney dysfunction in tenofovir-naïve children. The primary objective was to know the point prevalence of albuminuria and β2-microglobulinuria in HIV infected children aged 3-18 years receiving ART. Albuminuria and β2-microglobulinuria were used as surrogates for glomerular and tubular dysfunction respectively. The secondary objective was to determine their predictors. Cross-sectional study-design METHODS One hundred consecutive HIV